Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Anticonvulsants Unhelpful for Low Back Pain

Marilynn Larkin  |  July 7, 2018

NEW YORK (Reuters Health)—Solid evidence suggests that anticonvulsants provide no benefit for low back or lumbar radicular pain and a high risk of harm, researchers say.

“We started the study because these drugs were increasingly being used for low back pain and radiating leg pain, without the support of strong evidence of effectiveness,” principal investigator Dr. Christine Lin of the University of Sydney tells Reuters Health.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“I think the rate has soared because people want to avoid other strong medicines, such as opioids, and also because anticonvulsants are relatively new in their use for pain relief, thus offering a new option for people with pain,” she says by email. “In Australia, anticonvulsants were approved by the government for nerve pain in 2013.”

“We conducted our own trial on the anticonvulsant drug pregabalin in patients with sciatica, which showed that pregabalin was not effective,” she adds. “So the systematic review was to gather evidence beyond our trial and see what the summary of evidence says.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Lead author Dr. Oliver Enke, also of the University of Sydney, notes in a separate email, “Our institution also investigated the prescription of analgesia for spinal pain, which concluded that general practitioners’ analgesic management of spinal pain has become increasingly divergent from guideline recommendations.”

“Between 2013 and 2014, over 1.3 million prescriptions were written for pregabalin in Australia,” he tells Reuters Health, “and the prescription of anticonvulsants in primary care has increased by 535% in the last 10 years.”

“The fact that anticonvulsants are often advertised to be effective for ‘nerve pain’ may mislead the prescriber to assume efficacy for low back pain or sciatica,” he says.

For the current study, online July 3 in CMAJ, Drs. Lin, Enke and colleagues analyzed nine placebo-controlled randomized trials with a total of 859 participants (average age about 51). Four trials included participants with chronic low back pain with or without radiating leg pain and five included participants with lumbar radicular pain.1

Fourteen of 15 comparisons found anticonvulsants were not effective in reducing the pain or disability of low back or lumbar radicular pain.

Specifically, high-quality evidence from three trials that investigated gabapentin versus placebo for chronic low back pain with or without radiating leg pain showed no effect for pain in the short term or for lumbar radicular pain in the immediate term.

Similarly, high-quality evidence showed gabapentin was ineffective in the intermediate term.

Moderate-quality evidence exists that topiramate provided a “small clinically worthwhile” effect in the short-term.

Page: 1 2 | Single Page
Share: 

Filed under:Conditions Tagged with:anticonvulsive druglow back painPainPain Management

Related Articles

    Meet the Lumbar Spinal Stenosis Challenge

    August 1, 2007

    Limited evidence and diagnostic options make this increasing condition difficult to treat

    Pregabalin Is Ineffective for Sciatica

    May 8, 2017

    A recent small-scale study examined the efficacy of pregabalin in the treatment of neuropathic pain caused by sciatica, as well as its associated low back pain. Researchers found the treatment did not reduce leg pain better than placebo and resulted in more adverse events…

    Best Practices for Treating Non-Specific Low Back Pain

    December 16, 2015

    Low back pain (LBP) is one of the most common reasons for physician appointments. However, treatment results remain suboptimal, resulting in high rates of chronic pain, narcotic usage, surgery, depression and disability—all at great cost to individuals and the nation. One reason for this is the current practice of grouping all low back pain patients…

    The Complexity of Lumbar Spinal Stenosis

    June 10, 2012

    Challenges in diagnosis and management.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences